We provide end-to-end CDMO support across Pharmaceutical Development & Manufacturing → Drug Substance Development → Cytokine Development, with a focused offering for Interleukin-2 (IL-2). Our programs emphasize laboratory biotechnology, manufacturability, and analytical depth suitable for seamless downstream enablement.
Overview of Interleukin-2 (IL-2) Development
IL-2 is a compact, disulfide-stabilized cytokine whose activity depends on proper folding, controlled oxidation, and low aggregate content. Development hinges on selecting a fit-for-purpose expression system, tuning upstream conditions to minimize misfolding, and establishing robust purification with oxidation-state control. Because IL-2 can be sensitive to shear, pH, and ionic milieu, platformable formulation strategies are paired with orthogonal analytics to monitor identity, potency, purity, and degradants.
Our Services
The offering spans sequence/variant engineering for manufacturability, expression and cell line development, upstream and downstream process development, advanced analytics and bioassays.
Sequence & Variant Engineering Service
We assess IL-2 sequences for developability liabilities—aggregation-prone motifs, disulfide pairing risks, deamidation and oxidation hot spots—and propose limited, purpose-built sequence adjustments or fusion formats consistent with cytokine function. Workflows include in-silico screening, small-scale expression, and side-by-side biophysical and potency characterization to select a tractable candidate for scale-up.
Expression System & Cell Line Development Service
We establish E. coli or mammalian expression routes depending on target quality attributes. For E. coli, we optimize inclusion-body formation, solubilization, and refolding windows; for mammalian systems, we develop stable pools/clones with chemically defined media. Platform media/feed designs, process intensification levers, and early process parameters are documented for reproducibility.
Upstream Process Development Service
We create scalable upstream processes with controls for redox environment, induction strategy, temperature, and dissolved oxygen to promote correct folding and minimize off-pathway species. Design-of-experiments studies map critical parameters, while inline/at-line measurements track product titer and quality attributes relevant to IL-2 stability.
Analytical Characterization & Potency Service
We build orthogonal identity and purity packages (intact mass, peptide mapping, charge variants, size variants, host-cell impurities) alongside cytokine-relevant bioassays. Binding/functional readouts aligned with IL-2 receptor engagement are qualified for comparability.
We integrate cytokine know-how with rigorous drug-substance development to deliver IL-2 processes and analytics. Engage us to accelerate IL-2 development with practical platform strategies and clear, phase-appropriate data packages.
Frequently Asked Questions
Q1: Which expression system is most suitable for IL-2 in development?
Both E. coli and mammalian systems are viable. We recommend E. coli when speed, yield, and straightforward refolding are prioritized, and mammalian systems when specific post-translational quality targets are desired. We run small-scale feasibility in parallel to compare titer, folding efficiency, and quality attributes before locking the route.
Q2: How do you control IL-2 aggregation and oxidation during purification?
Controls include low-shear handling, carefully selected pH/ionic strength, antioxidant or chelator use where appropriate, and tight residence-time management. Polishing steps are configured to remove size variants, while hold-time and temperature limits are defined from stability studies to minimize oxidative drift and aggregate growth.
Q3: What potency assay strategy do you recommend for IL-2?
We implement an orthogonal potency package: a receptor-relevant functional assay for primary release/comparability, supported by biochemical surrogates (e.g., binding or signaling readouts). Assays are qualified with system suitability, acceptance criteria, and reference standard governance to ensure lot-to-lot continuity.
Our products and services are for research use only.
